La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Edesa Biotech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Edesa Biotech..

Edesa Biotech (NASDAQ:EDSA) Azioni, Catena delle Opzioni

Edesa Biotech

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Edesa Biotech Inc

Becton, Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) reported quarterly earnings of $3.81 per share which beat the analyst consensus estimate of $3.77 by 1.06 percent. The company reported quarterly sales of $5.437 billion which beat the analyst consensus estimate of $5.380 billion by 1.06 percent. This is a 6.88 percent increase over sales of $5.087 billion the same period last year.

Earnings

Earnings Beats

News

Becton, Dickinson Q4 2024 Adj. EPS $3.81 Beats $3.77 Estimate, Sales $5.437B Beat $5.380B Estimate

Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.58 by 10.34 percent. This is a 8.47 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $292.25 million which beat the analyst consensus estimate of $285.87 million by 2.23 percent. This is a 5.29 percent increase over sales of $277.55 million the same period last year.

PLNT

Planet Fitness Q3 2024 Adj EPS $0.64 Beats $0.58 Estimate, Sales $292.25M Beat $285.87M Estimate

Needham analyst John Todaro maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $17 to $18.

Price Target

Analyst Ratings

Core Scientific, Inc. - Class A Common Stock

CORZ

Needham Maintains Buy on Core Scientific, Raises Price Target to $18

Commodities

Markets

General

PG&E Is Increasing Its 5-year Capital Investment Plan By $1B For A Total Of $63B For 2024 Through 2028,  The Incremental Capital Has Also Already Been Financed Through The Recent Issuance Of Junior Subordinated Notes And PG&E Is Reaffirming Its 2025 To 2028 Equity Issuance Guidance Of $3B

The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024.&nbsp;

Dividends

BD Boosts Quarterly Dividend By 9.5% From $0.95 To $1.04 Per Common Share

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) with a Buy and maintains $27 price target.

Reiteration

EOLS

HC Wainwright & Co. Reiterates Buy on Evolus, Maintains $27 Price Target

Acushnet Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.81 by 9.88 percent. The company reported quarterly sales of $620.501 million which beat the analyst consensus estimate of $620.371 million by 0.02 percent. This is a 4.57 percent increase over sales of $593.381 million the same period last year.

GOLF

Acushnet Hldgs Q3 2024 GAAP EPS $0.89 Beats $0.81 Estimate, Sales $620.501M Beat $620.371M Estimate

Mitsubishi Estate Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MITEY#OTC">MITEY</a>) lowers FY2024 GAAP EPS guidance from $0.95 to $0.93. Raises FY2024 sales outlook from $10.71 billion to $10.72 billion.

Guidance

MITEY

Mitsubishi Estate Co expects FY2024 Revenue of JPY 1,596B; EPS JPY 137.93.

Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.12 by 8.33 percent. The company reported quarterly sales of $1.03 billion which met the analyst consensus estimate. This is a 3.56 percent decrease over sales of $1.07 billion the same period last year.

ELAN

Elanco Animal Health Q3 2024 Adj EPS $0.13 Beats $0.12 Estimate, Sales $1.03B Inline

Molson Coors Beverage Takes Majority Stake In ZOA Energy; Terms Not Disclosed

AngloGold Ashanti Q3 Adjusted EBITDA $746M, Up 339% Y/Y; Reaffirms Full-year Guidance For Gold Production, Costs And Capital Expenditure

By utilizing the cloud-native and modular capabilities of DeepHealth OS, ONRAD will implement a customized solutions roadmap targeted to streamline its clinical and operational workflows, enhancing productivity, and ultimately improving patient outcomes through AI-powered, unified data integration.

Health Care

Contracts

RDNT

RadNet Announced That ONRAD Has Selected RadNet's DeepHealth OS To Advance Its Next Generation Of Radiology Services

Haemonetics Reiterated FY25 Adjusted Earnings Per Diluted Share Outlook Of $4.45-$4.75 Vs. $4.59 Estimate

Haemonetics Projects Total Company FY25 Reported Revenue Growth Of 5%-8% (Reiterated); Sees Organic Revenue Growth Of 1%-4% (Prior View: 0-3%)

Ducommun (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DCO#NYSE">DCO</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.74 by 33.78 percent. The company reported quarterly sales of $201.41 million which beat the analyst consensus estimate of $194.10 million by 3.76 percent. This is a 2.63 percent increase over sales of $196.25 million the same period last year.

Ducommun Q3 2024 Adj EPS $0.99 Beats $0.74 Estimate, Sales $201.41M Beat $194.10M Estimate

Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>), the world's leading lithium producer, reported a challenging third quarter, revealing a net loss of $1.1b amidst a continued downturn in <a target="_blank" href="https://www.benzinga.com/topic/lithium" rel="noreferrer noopener">lithium prices</a>.
Despite a market slump, fueled by a supply surplus from China and a demand-dampening slower EV adoption – Albemarle saw a 16% rise in lithium sales volume year-over-year.
Management expects the downturn to endure, so it has announced measures to adjust to these market conditions: streamlining business units and announcing workforce reductions of 6-7% globally, primarily impacting non-manufacturing roles.
"Through our strategic review of Albemarle's cost and operating structure, we have identified significant opportunities to reduce costs, improve productivity, and decrease capital spending," <a target="_blank" href="https://www.albemarle.com/global/en/news/albemarle-reports-third-quarter-2024-results" rel="noreferrer noopener">stated</a> CEO Kent Masters. These efforts are projected to save the company $300 to $400 million annually.
Albemarle also plans to reduce capital expenditures significantly in 2025, setting a range of $800 million to $900 million to sustain its current assets. This budget cut aligns with the company's expectation that lithium prices may remain between $12 and $15 per kilogram for the foreseeable future.
Despite these challenges, Albemarle maintained its full-year outlook, citing improved productivity, higher lithium volumes, and long-term supply contracts, which helped offset the impact of declining market prices.
Looking forward, Albemarle and its peers remain hopeful that demand for lithium will surge later in the decade, particularly as North American EV sales hit record highs in the third quarter of 2024. The company expects EV prices to achieve parity with combustion-engine vehicles by 2025, supporting long-term growth in lithium demand.
The recent U.S. election has focused additional attention on the industry, as Donald Trump's return to office could favor domestic lithium production.
"A strong America cannot be dependent on imports from foreign adversaries for the critical minerals necessary to maintain our economic and military strength," Trump declared in a 2020 executive order.
Notably, Trump's final act before leaving office in 2021 was to green-light the Thacker Pass lithium mine, the largest known sedimentary lithium deposit.
His protectionist stance and close ties with Tesla CEO Elon Musk suggest that his policies may benefit domestic lithium producers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41769288/donald-trumps-victory-could-disrupt-commodities-put-australia-in-precarious-position" target="_blank" rel="noreferrer noopener">Donald Trump's Victory Could Disrupt Commodities, Put Australia In Precarious Position</a></li>
</ul>
Photo via Shutterstock

Albemarle Adjusts To Lower-For-Longer Lithium Prices, Cuts Capex, Announces Layoffs

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2">Fourth Quarter &amp; Full Year 2024 Financial Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="3">For the Fourth Quarter and Full Year 2024, the Company currently expects (dollars in millions):</td>
</tr>
<tr>
<td>Q4 2024</td>
<td rowspan="2">​</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">Unaudited</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">(dollars in millions)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenues</td>
<td>$460 - $490</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$180 - $196</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>ex-TAC Gross Profit&#x2A;</td>
<td>$205 - $221</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Adjusted EBITDA&#x2A;</td>
<td>$83 - $99</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-GAAP Net Income (Loss)&#x2A;</td>
<td>$37 - $53</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

TBLA

Taboola.com Expects Q4 Revenue Of $460M-$490M Vs $480.12M Est, Reiterated FY24 Revenue Of $1.735B-$1.765B Vs $1.75B Est

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

CHRS

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Canadian Tire Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CDNAF#OTC">CDNAF</a>) reported quarterly earnings of $2.63 per share. This is a 19 percent increase over earnings of $2.21 per share from the same period last year. The company reported $3.07 billion in sales this quarter. This is a 2.97 percent decrease over sales of $3.17 billion the same period last year.

CDNAF

Canadian Tire Corp Q3 Adj $2.63 Up From $2.21 YoY, Sales $3.07B Down From $3.17B YoY

RAISING 2024 GUIDANCE
For the full year of 2024, we are raising our guidance for both revenue and adjusted EBITDA. We now expect revenue to be in the range of $1.567 billion to $1.601 billion, up from the range of $1.557 billion to $1.591 billion. We now expect adjusted EBITDA to be in the range of $433 million to $448 million, up from the range of $423 million to $438 million.

ACIW

ACI Worldwide Raises 2024 Guidance: Now Expects Revenue Of $1.567B-$1.601B (Prior $1.557B-$1.591B Vs $1.577B Est.; Sees Adj. EBITDA Of $433M-$448M (Prior $423M-$438M)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) just reported results for the second quarter of 2024.<ul><li>Edesa Biotech reported earnings per share of -58 cents. This was above the analyst estimate for EPS of -69 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/edsa-stock-earnings-edesa-biotech-for-q2-of-2024/">EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EDSA Stock Earnings: Edesa Biotech Beats EPS for Q2 2024

An update from Edesa Biotech (EDSA) is now available. Edesa Biotech, Inc. shareholders have given the green light to a key amendment that boosts th...

Edesa Biotech Shareholders Approve Board and Compensation Plans

Edesa Biotech (EDSA) has released an update. Edesa Biotech's novel drug, paridiprubart, has been selected by the U.S. Biomedical Advanced Research ...

Edesa Biotech's ARDS Drug Chosen for US Trial

Vernon Bernardino, an analyst from H.C. Wainwright, reiterated the Buy rating on Edesa Biotech (EDSA – Research Report). The associated price targe...

Promising Outlook for Edesa Biotech's Paridiprubart: A Buy Rating Justified by BARDA-Backed ARDS Study and Broad Therapeutic Potential

Edesa Biotech GAAP EPS of -$0.52 beats by $0.06

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its third-quarter financials ...

Edesa Biotech Showcases Steady Q3 2024 Financials

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Edesa Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/edsa-stock-quote/">EDSA</a>) just reported results for the third quarter of 2024.<ul><li>Edesa Biotech reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -58 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/edsa-stock-earnings-edesa-biotech-for-q3-of-2024/">EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EDSA Stock Earnings: Edesa Biotech Beats EPS for Q3 2024

Buy Rating Affirmed for Edesa Biotech Amidst Strong Government Support and Promising Drug Pipeline

Edesa Biotech ( ($EDSA) ) has issued an update. Edesa Biotech, Inc. has partnered with H.C. Wainwright & Co., LLC to periodically sell its common s...

Edesa Biotech Partners with Wainwright for Share Sales

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple internati...

Comments

Edesa Biotech

Edesa Biotech (EDSA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO